Melqart Asset Management UK Ltd Acquires Shares of 183,351 Grifols, S.A. (NASDAQ:GRFS)

Melqart Asset Management UK Ltd purchased a new stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 183,351 shares of the biotechnology company's stock, valued at approximately $1,628,000.

Other institutional investors have also added to or reduced their stakes in the company. Brandes Investment Partners LP lifted its position in shares of Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company's stock worth $117,242,000 after purchasing an additional 1,481,924 shares during the period. Armistice Capital LLC lifted its position in shares of Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company's stock worth $49,759,000 after purchasing an additional 1,244,000 shares during the period. Highland Peak Capital LLC purchased a new position in Grifols during the 2nd quarter valued at about $5,991,000. Black Creek Investment Management Inc. lifted its position in Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company's stock valued at $77,799,000 after acquiring an additional 881,155 shares during the period. Finally, Whitebox Advisors LLC lifted its position in Grifols by 45.6% during the 2nd quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company's stock valued at $17,039,000 after acquiring an additional 846,940 shares during the period.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.

Grifols Price Performance

NASDAQ:GRFS traded up $0.05 on Wednesday, reaching $7.28. 1,483,196 shares of the stock traded hands, compared to its average volume of 1,872,966. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The company's fifty day simple moving average is $8.70 and its 200 day simple moving average is $8.10.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.